Diabetes is a common chronic disease that is characterized and defined by an elevated glucose level and that has grown in prevalence by 75% in the United States during a 20 year period ending in 2010 1 . The exact reason for this rising prevalence is not known with certainty; however a large body of evidence implicates changes in weight, caloric consumption, reduced physical activity and migration to urban versus rural dwellings. Regardless of the reasons for this growth, epidemiologic studies and analyses of administrative databases have repeatedly shown that people with diabetes are 2-3 times more likely to experience fatal and nonfatal cardiovascular outcomes than people without diabetes 2 . This high risk was the basis for the intentional inclusion of ambulatory adults with diabetes in a large number of recent cardiovascular outcomes trials that either recruited large subpopulations or people with diabetes or were wholly restricted to people with diabetes. These trials showed that therapies that were shown to be cardioprotective in people without diabetes will also reduce cardiovascular outcomes in ambulatory people with diabetes. These include blood pressure lowering 3 , LDL lowering with statins 4 , ACE inhibitors 5 or angiotensin receptor blockers 6 and bypass surgery 7 . During the same period other therapies were shown to have a neutral effect on cardiovascular outcomes in people with diabetes including vitamin E 8 , omega 3 fatty acids 9 , and basal insulin 10 .
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The first approach started with drugs that lower glucose levels by increasing the effectiveness of secreted insulin. After 3 years these included metformin (in 75%) and rosiglitazone (in 55%).
The second approach used insulin (in 61%) and/or drugs such as sulfonlyureas (52%) that increase insulin secretion. During a mean follow-up period of 5.3 years, participants allocated to these 2 approaches achieved mean HbA1c levels that differed by less than 0.5% and used a similar set of cardioprotective therapies. Most importantly, these 2 different approaches to glucose lowering had similar effects on the primary outcome of death and the secondary composite outcome of death, myocardial infarction or stroke.
The results of the BARI 2D trial are of particular interest in light of a highly publicized debate regarding the cardiovascular safety of rosiglitazone and concerns that rosiglitazone may increase the risk of death and myocardial infarctions. These concerns were mainly based on meta-analyses of cardiovascular events collected in small noncardiovascular trials and on analyses of administrative databases. Nevertheless they received much publicity and led the US Federal Drug Administration to restrict the drug's availability and suspend its approval for a large ongoing cardiovascular outcomes trial pending further cardiovascular safety data 21 .
The post hoc epidemiologic analysis of the BARI 2D trial reported in this issue of the journal 22 provides data that are pertinent to this issue. In this report the investigators used 2 different approaches to assess the cardiovascular effects of rosiglitazone during 3025 patientyears follow-up of participants exposed to rosiglitazone versus 7146 patient-years follow-up of participants with no thiazolidinedione exposure during the study. First, using regression models that adjusted for differences in baseline characteristics and use of other glucose-lowering drugs, composite outcome of death, myocardial infarction or stroke.
The results of the BARI 2D trial are of particular interest in light of a highly publicized P=0.29) and was associated with a reduced hazard of the composite cardiovascular outcome (HR 0.72, 95% CI 0.55 to 0.93, p=0.01). Second, using a propensity-matched approach that compared incident cardiovascular outcomes in participants taking rosiglitazone during the first 6 months of the trial to participants on no thiazolidinedione during that time but who were estimated to have the same propensity for being prescribed rosiglitazone, no differences in any cardiovascular outcome was observed. Both approaches reported nonsignificant increases in incident heart failure and significant increases in fractures with rosiglitazone.
As this is an epidemiologic analysis of data collected within a randomized controlled trial, it provides a lower level of evidence than could be provided by a carefully done prospective randomized controlled trial. Indeed, like all epidemiologic analyses it cannot definitively separate the effect of the drug from the reasons that the drug was prescribed and may therefore provide a biased estimate of the drug's effect on cardiovascular outcomes. Indeed, the confounding that is inherent in all such analyses is the likeliest explanation for discordant cardiovascular effects of rosiglitazone observed in the published epidemiologic analyses 21, 23 .
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a sulfonylurea is noninferior to the use of metformin plus a sulfonylurea with respect to death and serious cardiovascular outcomes 19 , and which recently underwent rigorous independent scrutiny, reanalysis and confirmation 21 . These data therefore provide no support for assertions that rosiglitazone increases deaths or ischemic cardiovascular outcomes and are most consistent with a position of clinical equipoise regarding its long-term effect on cardiovascular outcomes.
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